Bulletin
Investor Alert

Allakos Inc.

NAS: ALLK

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Allakos Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 27, 2022, 7:11 p.m.

ALLK
/zigman2/quotes/203639566/composite

$

6.18

Change

-0.02 -0.32%

Volume

Volume 19,774

Quotes are delayed by 20 min

/zigman2/quotes/203639566/composite

Today's close

$ 6.52

$ 6.20

Change

-0.32 -4.91%

Day low

Day high

$6.16

$6.65

Open

52 week low

52 week high

$6.16

$157.98

Open

Company Description

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocy...

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.

Valuation

Price to Book Ratio

11.36

Enterprise Value to EBITDA

1.69

Total Debt to Enterprise Value

0.01

Efficiency

Income Per Employee

-1,227,840.00

Liquidity

Current Ratio

29.81

Quick Ratio

29.81

Cash Ratio

29.35

Profitability

Return on Assets

-24.82

Return on Equity

-26.69

Return on Total Capital

-26.13

Return on Invested Capital

-25.56

Capital Structure

Total Debt to Total Equity

6.61

Total Debt to Total Capital

6.20

Total Debt to Total Assets

6.01

Long-Term Debt to Equity

6.54

Long-Term Debt to Total Capital

6.13

Officers and Executives

Name Age Officer Since Title
Dr. Robert Alexander 50 2017 Chief Executive Officer & Director
Dr. Adam L. Tomasi 50 2017 President & Chief Operating Officer
Mr. Harlan Baird Radford - 2021 Chief Financial Officer
Dr. Ruby Casareno - - Vice President-Technical Operations
Dr. Craig Paterson - 2021 SVP-Clinical Development & Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/02/2021 Robert Alexander
Chief Executive Officer; Director 		20,241   Derivative/Non-derivative trans. at $78.69 per share. 1,592,764
12/02/2021 Adam L. Tomasi
President and COO 		13,067   Derivative/Non-derivative trans. at $78.69 per share. 1,028,242
12/01/2021 Robert Alexander
Chief Executive Officer; Director 		51,681   Award at $0 per share. 0
12/01/2021 Adam L. Tomasi
President and COO 		33,362   Award at $0 per share. 0
12/01/2021 Mark A. Asbury
CLO 		26,003   Award at $0 per share. 0
12/01/2021 Harlan Baird Radford
Chief Financial Officer 		24,255   Award at $0 per share. 0
09/28/2021 Steven P. James
Director 		4,000   Disposition at $108.12 per share. 432,480
09/28/2021 Steven P. James
Director 		4,000   Derivative/Non-derivative trans. at $0.52 per share. 2,080
09/02/2021 Robert Alexander
Chief Executive Officer; Director 		3,985   Derivative/Non-derivative trans. at $91.66 per share. 365,265
09/02/2021 Adam L. Tomasi
President and COO 		2,346   Derivative/Non-derivative trans. at $91.66 per share. 215,034
09/02/2021 Mark A. Asbury
CLO 		698   Derivative/Non-derivative trans. at $91.66 per share. 63,978
08/31/2021 Adam L. Tomasi
President and COO 		64,148   Derivative/Non-derivative trans. at $4.31 per share. 276,477
06/15/2021 Adam L. Tomasi
President and COO 		20,000   Derivative/Non-derivative trans. at $0.69 per share. 13,800
06/15/2021 Adam L. Tomasi
President and COO 		20,000   Disposition at $91.03 per share. 1,820,600
06/14/2021 Adam L. Tomasi
President and COO 		20,000   Derivative/Non-derivative trans. at $0.69 per share. 13,800
06/14/2021 Adam L. Tomasi
President and COO 		20,000   Disposition at $91.62 per share. 1,832,400
06/07/2021 Adam L. Tomasi
President and COO 		2,487   Disposition at $92.03 per share. 228,878
06/04/2021 Robert Alexander
Chief Executive Officer; Director 		5,482   Disposition at $89.64 per share. 491,406
06/04/2021 Robert Alexander
Chief Executive Officer; Director 		3,597   Disposition at $89.62 per share. 322,363
06/04/2021 Robert Alexander
Chief Executive Officer; Director 		14,516   Disposition at $89.64 per share. 1,301,214
06/04/2021 Adam L. Tomasi
President and COO 		642   Disposition at $90.26 per share. 57,946
06/04/2021 Henrik Sandvad Rasmussen
Chief Medical Officer 		2,435   Disposition at $89.6 per share. 218,176
06/04/2021 Robert Alexander
Chief Executive Officer; Director 		14,516   Derivative/Non-derivative trans. at $0.69 per share. 10,016
06/03/2021 Robert Alexander
Chief Executive Officer; Director 		5,484   Disposition at $92.09 per share. 505,021
06/03/2021 Robert Alexander
Chief Executive Officer; Director 		14,517   Disposition at $92.14 per share. 1,337,596
06/03/2021 Robert Alexander
Chief Executive Officer; Director 		4,003   Derivative/Non-derivative trans. at $92.2 per share. 369,076
06/03/2021 Adam L. Tomasi
President and COO 		1,777   Derivative/Non-derivative trans. at $92.2 per share. 163,839
06/03/2021 Henrik Sandvad Rasmussen
Chief Medical Officer 		834   Derivative/Non-derivative trans. at $92.2 per share. 76,894
06/03/2021 Mark A. Asbury
CLO 		734   Derivative/Non-derivative trans. at $92.2 per share. 67,674
06/03/2021 Robert Alexander
Chief Executive Officer; Director 		14,517   Derivative/Non-derivative trans. at $0.69 per share. 10,016
/news/latest/company/us/allk

MarketWatch News on ALLK

  1. Biotech M&A Has Been Slow This Year. Why It Might Get Busier.

    7:32 a.m. May 21, 2021

    - Barron's Online

  2. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  3. Allakos started at buy at BofA Securities

    10:31 a.m. Jan. 15, 2021

    - Tomi Kilgore

  5. Allakos stock jumps in afternoon trading

    3:24 p.m. Dec. 4, 2019

    - Jaimy Lee

  6. Allakos's stock rally adds over $2 billion to biotech's market cap

    2:54 p.m. Dec. 4, 2019

    - Tomi Kilgore

  7. Allakos's stock runs up 43% to record high

    2:53 p.m. Dec. 4, 2019

    - Tomi Kilgore

  8. Charting a bullish reversal, S&P 500 extends rally from major support

    10:53 a.m. Aug. 19, 2019

    - Michael Ashbaugh

  9. How 2018’s Major IPOs Performed

    8:39 p.m. Dec. 21, 2018

    - Barron's Online

  10. Glenn Krevlin Wants a Seat at Destination XL

    12:22 a.m. Sept. 15, 2018

    - Barron's Online

  11. ADP and Pershing Square Face Off

    9:35 p.m. Aug. 3, 2018

    - Barron's Online

  12. Biotech Allakos shares surge more than 70% in trading debut

    12:50 p.m. July 19, 2018

    - Ciara Linnane

  13. Allakos shares surge 73% in trading debut

    12:48 p.m. July 19, 2018

    - Ciara Linnane

  14. Biotech Allakos prices IPO at $18, above price range

    6:50 a.m. July 19, 2018

    - Ciara Linnane

  15. Allakos prices IPO at $18 a share

    6:41 a.m. July 19, 2018

    - Ciara Linnane

/news/nonmarketwatch/company/us/allk

Other News on ALLK

  3. Tracking Baker Brothers Portfolio - Q3 2021 Update

    10:32 p.m. Jan. 4, 2022

    - Seeking Alpha

  6. Allakos price target cut to $20 from $230 at H.C. Wainwright

    7:07 a.m. Dec. 28, 2021

    - Seeking Alpha

  7. Wall Street Breakfast: What Moved Markets

    3:20 p.m. Dec. 24, 2021

    - Seeking Alpha

  9. ZEV, GP and NES among mid-day movers

    12:30 p.m. Dec. 23, 2021

    - Seeking Alpha

  10. Allakos: Sad End To A Promising Asset

    12:25 p.m. Dec. 23, 2021

    - Seeking Alpha

  13. Allakos rebounds amid bearish views on trial setback

    8:27 a.m. Dec. 23, 2021

    - Seeking Alpha

  14. Warning: ALLK is at high risk of performing badly

    4:39 a.m. Dec. 23, 2021

    - Seeking Alpha

  16. PAVM, BLPH and LTRY among mid-day movers

    12:28 p.m. Dec. 22, 2021

    - Seeking Alpha

  17. Why Allakos Stock Is Crashing Today

    10:41 a.m. Dec. 22, 2021

    - Motley Fool

  21. Loading more headlines...

At a Glance

Allakos, Inc.

975 Island Drive

Suite 201

Redwood City, California 94065

Phone

1 6505975002

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

View SEC Filings

Revenue

N/A

Net Income

$-153.48M

Employees

125.00

Annual Report for ALLK

/news/pressrelease/company/us/allk

Press Releases on ALLK

  13. Allakos Appoints Baird Radford as Chief Financial Officer

    3:01 p.m. April 19, 2021

    - GlobeNewswire

  15. RiverVest Venture Partners Closes $275 Million Life Sciences Fund

    1:23 p.m. March 24, 2021

    - BusinessWire - BZX

Link to MarketWatch's Slice.